Improving profitability trend continues this year
​We upgrade our recommendation for Okmetic to Buy (Accumulate) and raise our target price to 8.0 EUR (7.7 EUR) after a solid Q4-report. Okmetic’s investment case is based on Okmetic’s solid long term growth fundamentals, improving profitability trend, low earnings based valuation (P/E 13x) and strong dividend yield (>6 %).
Inderes was founded 2009 and is a company that focuses on equity research. Our goal is to contribute to the functioning of the capital markets by acting as an information link between companies and investors. We are one of the largest equity research teams in Helsinki with the strength of 9 professionals. Inderes Equity Research is an award-winning equity research team, which is independent from banking activities. Several of our analysts are top ranked on the Bloomberg BARR-ranking and have won several Starmine rewards. Our company is majority-owned by the staff.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.